Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

How our clients use DrugPatentWatch

DrugPatentWatch Database Preview

HORIZANT Drug Profile

« Back to Dashboard

Which patents cover Horizant, and what substitute generic drugs are available?

Horizant is a drug marketed by Arbor Pharms Llc and is included in one NDA. There are six patents protecting this drug.

This drug has one hundred and forty patent family members in twenty-five countries.

The generic ingredient in HORIZANT is gabapentin enacarbil. There are twenty-six drug master file entries for this compound. Two suppliers are listed for this compound. Additional details are available on the gabapentin enacarbil profile page.

Summary for Tradename: HORIZANT

Patents:6
Applicants:1
NDAs:1
Suppliers / Packagers: see list2
Bulk Api Vendors: see list24
Clinical Trials: see list4
Patent Applications: see list68
Drug Prices:see details
DailyMed Link:HORIZANT at DailyMed

Pharmacology for Tradename: HORIZANT

Applicant Tradename Generic Name Dosage NDA Approval Date Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Arbor Pharms Llc
HORIZANT
gabapentin enacarbil
TABLET, EXTENDED RELEASE;ORAL022399-002Dec 13, 2011RXYesNo8,048,917► SubscribeYY ► Subscribe
Arbor Pharms Llc
HORIZANT
gabapentin enacarbil
TABLET, EXTENDED RELEASE;ORAL022399-001Apr 6, 2011RXYesYes► Subscribe► Subscribe
Arbor Pharms Llc
HORIZANT
gabapentin enacarbil
TABLET, EXTENDED RELEASE;ORAL022399-002Dec 13, 2011RXYesNo8,026,279► SubscribeYY ► Subscribe
Arbor Pharms Llc
HORIZANT
gabapentin enacarbil
TABLET, EXTENDED RELEASE;ORAL022399-001Apr 6, 2011RXYesYes8,686,034► Subscribe ► Subscribe
Arbor Pharms Llc
HORIZANT
gabapentin enacarbil
TABLET, EXTENDED RELEASE;ORAL022399-002Dec 13, 2011RXYesNo6,818,787► SubscribeYY ► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Non-Orange Book Patents for Tradename: HORIZANT

For Orange Book-listed patents (shown in the main table above) generic applications must certify that the listed patents are expired, invalid, or will not be infringed by generic entry.

The non-Orange Book patents listed below do not require formal certifications, so they do not automatically impede generic entry. Instead, they represent potential opportunities for branded firms to block generic entry through patent infringment challenges.

Patent No. Title Estimated Patent Expiration
8,367,722Methods of using prodrugs of pregabalin► Subscribe
6,833,140 Orally administered dosage forms of GABA analog prodrugs having reduced toxicity► Subscribe
7,423,169Methods for synthesis of acyloxyalkyl derivatives of GABA analogs► Subscribe
8,906,412GABA analog prodrug sustained release oral dosage forms► Subscribe
7,790,708Prodrugs of GABA analogs, compositions and uses thereof► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Because of the complexity of determining patent expiration dates it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

International Patent Family for Tradename: HORIZANT

Country Document Number Estimated Expiration
World Intellectual Property Organization (WIPO)2004052844► Subscribe
European Patent Office1811986► Subscribe
MexicoPA06003043► Subscribe
China101434572► Subscribe
Israel165687► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Due to the complexity of determining patent expirations even in a single country, compounded by the diversity of global patent laws, it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

« Back to Dashboard

For more information try a trial or see the database preview and plans and pricing

How our clients use DrugPatentWatch

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

`abc